论文部分内容阅读
支架血栓形成(Stent Thrombosis,ST)是冠心病介入治疗的严重并发症,可对人体造成灾难性的后果。与普通金属支架(BMS)比较,药物洗脱支架(DES)可明显减少再狭窄率和靶病变的血运重建率。植入支架后可发生早期、晚期、极晚期支架血栓形成,其发生机制并不完全相同。抗血小板、抗凝、调脂治疗可能降低ST的发生率。个体化手术及个体化药物治疗,在解决冠脉血运重建的同时,可减少再狭窄率和降低ST的发生率。ST高危病人在植入支架后应该规律随访,加强对患者的健康教育。
Stent Thrombosis (ST) is a serious complication of interventional therapy of coronary heart disease, which can have disastrous consequences for the human body. Compared with BMS, drug-eluting stents (DES) can significantly reduce the rate of restenosis and target revascularization. Stent implantation can occur early, late, very late stent thrombosis, its mechanism is not exactly the same. Anti-platelet, anticoagulation, lipid-lowering treatment may reduce the incidence of ST. Individualized surgery and individualized drug treatment, in addressing coronary revascularization at the same time, can reduce the rate of restenosis and reduce the incidence of ST. ST high-risk patients should follow the regular follow-up after stent implantation, to enhance the health education of patients.